Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166215 · ClinicalTrials.gov registry record · Phase 1
Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03166215 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 18 participants.
The verdict
NCT03166215, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.
Interventions
- DRUG Placebo
- DRUG TAK-935
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-08-17 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03166215
The ClinicalTrials.gov registry entry for NCT03166215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03166215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03166215 about?
NCT03166215 is a clinical study titled "Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies". The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.
What is the current status of trial NCT03166215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-08-17. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT03166215?
The interventions under investigation include: Placebo (DRUG), TAK-935 (DRUG).
Who is sponsoring clinical trial NCT03166215?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.